Blueprint Medicines Corporation NASDAQ:BPMC

Founder-led company

Blueprint Medicines stock price today

$129.46
+40.06
+44.81%
Financial Health
0
1
2
3
4
5
6
7
8
9

Blueprint Medicines stock price monthly change

-24.10%
month

Blueprint Medicines stock price quarterly change

-24.10%
quarter

Blueprint Medicines stock price yearly change

-3.71%
year

Blueprint Medicines key metrics

Market Cap
5.66B
Enterprise value
2.41B
P/E
-4.57
EV/Sales
11.81
EV/EBITDA
-4.60
Price/Sales
11.81
Price/Book
4.68
PEG ratio
-0.33
EPS
-4.76
Revenue
282.20M
EBITDA
-434.55M
Income
-288.28M
Revenue Q/Q
51.87%
Revenue Y/Y
37.93%
Profit margin
-273.24%
Oper. margin
-263.44%
Gross margin
91.27%
EBIT margin
-263.44%
EBITDA margin
-153.98%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Blueprint Medicines stock price history

Blueprint Medicines stock forecast

Blueprint Medicines financial statements

Average Price Target
Last Year

$127

Potential downside: -1.90%

Based on estimate of 4 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Blueprint Medicines Corporation (NASDAQ:BPMC): Profit margin
Jun 2023 57.57M -132.79M -230.66%
Sep 2023 56.56M -133.71M -236.38%
Dec 2023 71.95M -110.91M -154.14%
Mar 2024 96.11M 89.13M 92.74%
Blueprint Medicines Corporation (NASDAQ:BPMC): Earnings per share (EPS)
2023-08-02 -2.55 -2.68
Blueprint Medicines Corporation (NASDAQ:BPMC): Debt to assets
Jun 2023 1106445000 795.31M 71.88%
Sep 2023 1105299000 902.68M 81.67%
Dec 2023 1049250000 918.64M 87.55%
Mar 2024 1038474999 727.78M 70.08%
Blueprint Medicines Corporation (NASDAQ:BPMC): Cash Flow
Jun 2023 -130.47M 32.06M 5.29M
Sep 2023 -104.48M -9.58M 98.39M
Dec 2023 -78.92M 78.76M 15.52M
Mar 2024 -101.51M 77.13M 66.96M

Blueprint Medicines alternative data

Blueprint Medicines Corporation (NASDAQ:BPMC): Employee count
Aug 2023 651
Sep 2023 660
Oct 2023 660
Nov 2023 661
Dec 2023 661
Jan 2024 661
Feb 2024 661
Mar 2024 655
Apr 2024 655
May 2024 655
Jun 2024 645
Jul 2024 645

Blueprint Medicines other data

100.00% 0.00%
of BPMC is owned by hedge funds
58.93M -97.29K
shares is hold by hedge funds

Blueprint Medicines Corporation (NASDAQ:BPMC): Insider trades (number of shares)
Period Buy Sel
Jan 2024 0 25000
Feb 2024 0 5000
Mar 2024 0 118534
May 2024 0 55648
Jun 2024 0 88149
Jul 2024 0 12667
Aug 2024 0 46322
Sep 2024 0 19702
Oct 2024 0 3633
Nov 2024 0 29451
Dec 2024 0 1819
Transaction Date Insider Security Shares Price per share Total value Source
Option
HURLEY ARIEL officer: PRINCIPA.. Common Stock 1,600 $15.01 $24,016
Sale
HURLEY ARIEL officer: PRINCIPA.. Common Stock 1,200 $92.88 $111,456
Sale
HURLEY ARIEL officer: PRINCIPA.. Common Stock 619 $93.99 $58,180
Option
HURLEY ARIEL officer: PRINCIPA.. Stock Option (Right to Buy) 1,600 $15.01 $24,016
Sale
HAVILAND KATE officer: CHIEF EXECUTIVE OFFICER
Common Stock 400 $95.4 $38,160
Sale
HAVILAND KATE officer: CHIEF EXECUTIVE OFFICER
Common Stock 1,746 $96.74 $168,908
Sale
HAVILAND KATE officer: CHIEF EXECUTIVE OFFICER
Common Stock 207 $97.76 $20,236
Sale
ROSSI CHRISTINA officer: CHIEF OPERATING OFFICER
Common Stock 2,274 $95.1 $216,257
Sale
COATS LONNEL director Common Stock 9,824 $94.87 $932,003
Option
COATS LONNEL director Common Stock 1,312 $76.24 $100,027
Wednesday, 18 December 2024
prnewswire.com
Saturday, 7 December 2024
prnewswire.com
Friday, 29 November 2024
zacks.com
Friday, 15 November 2024
seekingalpha.com
Thursday, 14 November 2024
benzinga.com
Thursday, 31 October 2024
zacks.com
Wednesday, 30 October 2024
seekingalpha.com
zacks.com
prnewswire.com
Thursday, 24 October 2024
zacks.com
Wednesday, 23 October 2024
zacks.com
Monday, 21 October 2024
zacks.com
Wednesday, 16 October 2024
prnewswire.com
Tuesday, 15 October 2024
zacks.com
Wednesday, 11 September 2024
accesswire.com
Tuesday, 10 September 2024
prnewswire.com
Monday, 9 September 2024
accesswire.com
Saturday, 7 September 2024
accesswire.com
Friday, 6 September 2024
accesswire.com
Thursday, 5 September 2024
accesswire.com
Wednesday, 4 September 2024
accesswire.com
Tuesday, 3 September 2024
accesswire.com
Monday, 2 September 2024
accesswire.com
Sunday, 1 September 2024
accesswire.com
Saturday, 31 August 2024
accesswire.com
Friday, 30 August 2024
accesswire.com
Thursday, 29 August 2024
accesswire.com
Wednesday, 28 August 2024
accesswire.com
Tuesday, 27 August 2024
accesswire.com
Monday, 26 August 2024
accesswire.com
  • What's the price of Blueprint Medicines stock today?

    One share of Blueprint Medicines stock can currently be purchased for approximately $129.46.

  • When is Blueprint Medicines's next earnings date?

    Unfortunately, Blueprint Medicines's (BPMC) next earnings date is currently unknown.

  • Does Blueprint Medicines pay dividends?

    No, Blueprint Medicines does not pay dividends.

  • How much money does Blueprint Medicines make?

    Blueprint Medicines has a market capitalization of 5.66B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22.22% to 249.38M US dollars. Blueprint Medicines made a loss 506.98M US dollars in net income (profit) last year or -$2.68 on an earnings per share basis.

  • What is Blueprint Medicines's stock symbol?

    Blueprint Medicines Corporation is traded on the NASDAQ under the ticker symbol "BPMC".

  • What is Blueprint Medicines's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Blueprint Medicines?

    Shares of Blueprint Medicines can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Blueprint Medicines's key executives?

    Blueprint Medicines's management team includes the following people:

    • Mr. Jeffrey W. Albers J.D., M.B.A., MBA Chairman, Chief Executive Officer & Pres(age: 54, pay: $1,200,000)
    • Ms. Kathryn Haviland Chief Operating Officer(age: 49, pay: $733,960)
    • Ms. Tracey L. McCain Esq. Executive Vice President, Chief Legal Officer, Chief Compliance officer & Sec.(age: 57, pay: $716,830)
    • Dr. Fouad Namouni M.D. Pres of R&D(age: 56, pay: $661,580)
    • Mr. Michael Landsittel Chief Financial Officer & Treasurer(age: 53, pay: $585,500)
    • Mr. Alexis A. Borisy A.M. Co-Founder & Director(age: 53, pay: $45,000)
  • Is Blueprint Medicines founder-led company?

    Yes, Blueprint Medicines is a company led by its founder Mr. Alexis A. Borisy A.M..

  • How many employees does Blueprint Medicines have?

    As Jul 2024, Blueprint Medicines employs 645 workers, which is 2% less then previous quarter.

  • When Blueprint Medicines went public?

    Blueprint Medicines Corporation is publicly traded company for more then 10 years since IPO on 30 Apr 2015.

  • What is Blueprint Medicines's official website?

    The official website for Blueprint Medicines is blueprintmedicines.com.

  • Where are Blueprint Medicines's headquarters?

    Blueprint Medicines is headquartered at 45 Sidney Street, Cambridge, MA.

  • How can i contact Blueprint Medicines?

    Blueprint Medicines's mailing address is 45 Sidney Street, Cambridge, MA and company can be reached via phone at +61 73747580.

  • What is Blueprint Medicines stock forecast & price target?

    Based on 4 Wall Street analysts` predicted price targets for Blueprint Medicines in the last 12 months, the avarage price target is $127. The average price target represents a -1.90% change from the last price of $129.46.

Blueprint Medicines company profile:

Blueprint Medicines Corporation

blueprintmedicines.com
Exchange:

NASDAQ

Full time employees:

638

Industry:

Biotechnology

Sector:

Healthcare

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

45 Sidney Street
Cambridge, MA 02139

CIK: 0001597264
ISIN: US09627Y1091
CUSIP: 09627Y109